

Characterization of Iodothyronine Sulfatase Activities in Human and Rat Liver and Placenta

MONIQUE H. A. KESTER, ELLEN KAPTEIN, CAREN H. VAN DIJK, THIRZA J. ROEST, DICK TIBBOEL, MICHAEL W. H. COUGHTRIE, AND THEO J. VISSER

Department of Internal Medicine, Erasmus University Medical School (M.H.A.K., E.K., C.H.V.D., T.J.R., T.J.V.), 3000 DR Rotterdam, The Netherlands; Department of Pediatric Surgery, Sophia Children's Hospital (M.H.A.K., D.T.), 3015 GJ Rotterdam, The Netherlands; and Department of Biochemical Medicine, University of Dundee (M.W.H.C.), Dundee DD1 9SY, Scotland, United Kingdom

In conditions associated with high serum iodothyronine sulfate concentrations, e.g. during fetal development, desulfation of these conjugates may be important in the regulation of thyroid hormone homeostasis. However, little is known about which sulfatases are involved in this process. Therefore, we investigated the hydrolysis of iodothyronine sulfates by homogenates of V79 cells expressing the human arylsulfatases A (ARSA), B (ARSB), or C (ARSC; steroid sulfatase), as well as tissue fractions of human and rat liver and placenta. We found that only the microsomal fraction from liver and placenta hydrolyzed iodothyronine sulfates. Among the recombinant enzymes only the endoplasmic reticulum-associated ARSC showed activity toward iodothyronine sulfates; the soluble lysosomal ARSA and ARSB were inactive. Recombinant ARSC as well as human placenta microsomes hydrolyzed iodothyronine sulfates with a substrate preference for 3,3'-diiodothyronine sulfate (3,3'-T₂S) ~ T₃ sulfate (T₃S) ≫ rT₃S ~ T₄S, whereas human and rat liver microsomes showed a prefer-

ence for 3,3'-T₂S > T₃S ≫ rT₃S ~ T₄S. ARSC and the tissue microsomal sulfatases were all characterized by high apparent K_m values (>50 μM) for 3,3'-T₂S and T₃S. Iodothyronine sulfatase activity determined using 3,3'-T₂S as a substrate was much higher in human liver microsomes than in human placenta microsomes, although ARSC is expressed at higher levels in human placenta than in human liver. The ratio of estrone sulfate to T₂S hydrolysis in human liver microsomes (0.2) differed largely from that in ARSC homogenate (80) and human placenta microsomes (150). These results suggest that ARSC accounts for the relatively low iodothyronine sulfatase activity of human placenta, and that additional arylsulfatase(s) contributes to the high iodothyronine sulfatase activity in human liver. Further research is needed to identify these iodothyronine sulfatases, and to study the physiological importance of the reversible sulfation of iodothyronines in thyroid hormone metabolism. (*Endocrinology* 143: 814–819, 2002)

SULFATION IS AN important metabolic pathway that facilitates the inactivation and elimination of lipophilic exogenous and endogenous compounds, including thyroid hormones, by increasing their water solubility (1–3). A more important purpose for the sulfation of thyroid hormones is to facilitate their degradation by the type I iodothyronine deiodinase (D1) (4–7). D1 catalyzes the outer ring deiodination (activation) of T₄ to T₃ as well as the inner ring deiodination (IRD; inactivation) of T₄ to rT₃ and of T₃ to 3,3'-diiodothyronine (3,3'-T₂) (5). As IRD of sulfated T₄ and T₃ by D1 is accelerated 40- to 200-fold, whereas outer ring deiodination of T₄ sulfate (T₄S) is completely blocked (4–7), sulfation has an important role in the irreversible inactivation of thyroid hormone by D1. However, when D1 activity is low or clearance of iodothyronine sulfates is otherwise impaired, inactivation of thyroid hormone by sulfation may be reversible due to the expression of arylsulfatases in different tissues (8–10) or the presence of bacterial sulfatases in the intestine (11). Strongly elevated iodothyronine sulfate concentrations have been found in fetal and neonatal serum and in amniotic fluid in humans and sheep (12–16). Thyroid hormone is essential for the normal fetal development of several organs,

in particular the brain (17–20). Therefore, it has been speculated that these iodothyronine sulfates, especially T₃S, function as a pool of inactive thyroid hormone from which the active hormone is released in a tissue-specific and development stage-dependent manner (7, 9, 12, 14, 21). Iodothyronine sulfatase activities are present in human fetal liver and lung, and become undetectable in lung after birth (22). In rats, which are born immature compared with humans, hepatic T₃S sulfatase activity progressively increases after birth until 2 months of age (23).

Hydrolysis of sulfate conjugates is an enzymatic process, and multiple arylsulfatases have now been identified (24). Arylsulfatase A (ARSA) and arylsulfatase B (ARSB) are soluble enzymes, localized in lysosomes. To date, sulfated glycolipids have been identified as endogenous substrates for ARSA, whereas ARSB has a known substrate specificity for dermatan sulfate and chondroitin sulfate (25). These sulfatases are widely distributed, although in the pig ARSA activity is 20–60 times higher in the thyroid than in other tissues (26). Arylsulfatase C (ARSC), also termed steroid sulfatase, is located in the endoplasmic reticulum, and hydrolyzes steroid sulfates such as dehydroepiandrosterone sulfate (DHEAS), estrone sulfate (E1S), and cholesterol sulfate (25). We have recently demonstrated that iodothyronines are good substrates for estrogen sulfotransferase (27). Therefore, it seems logical to assume that iodothyronine sulfates are also good substrates for the steroid sulfatase ARSC. This

Abbreviations: ARSA, Arylsulfatase A; ARSB, arylsulfatase B; ARSC, arylsulfatase C; BTP, bis-Tris propane; DHEAS, dehydroepiandrosterone sulfate; E1S, estrone sulfate; IRD, inner ring deiodination; PTU, 6-n-propyl-2-thiouracil; 3,3'-T₂, 3,3'-diiodothyronine.

isoenzyme is expressed in many tissues, including placenta and liver (28–31). In the placenta, ARSC plays a major role in estrogen biosynthesis from DHEAS, which is mainly produced in the fetal adrenal gland and is converted to 16 α -hydroxy-DHEAS by the fetal liver (32). Recently, a group of novel ARS genes was identified, clustered on Xp22.3 (33–35), near the ARSC gene. ARSD α and - β and ARSF have been localized in the endoplasmic reticulum, whereas ARSE is located in the Golgi apparatus (35, 36). The endogenous substrates for these arylsulfatases remain to be identified, although neither ARSE nor ARSF hydrolyzes steroid sulfates (33–36). ARSD does not appear to act as a conventional arylsulfatase, as no such activity has yet been determined for the recombinant protein (34, 35). They also differ from ARSC in that they are thermolabile.

Earlier studies demonstrated T₃S sulfatase activities in human and rat liver microsomes and in rat hepatocytes (9, 21). However, not much is known about which sulfatases are responsible for the hydrolysis of sulfated iodothyronines. Therefore, we studied the arylsulfatases ARSA, ARSB, and ARSC and the sulfatase activities in human and rat liver and placenta using iodothyronine sulfates as substrates to determine whether these arylsulfatases are involved in hydrolysis of thyroid hormone sulfates in tissues.

Materials and Methods

Materials

Rat livers were isolated from adult male Wistar rats, and normal human liver was obtained at surgery for liver tumors. Normal human placental tissue was obtained at spontaneous, full-term delivery, and rat placenta was obtained after cesarean section at 20 d gestational age. Approval was obtained from institutional committees. Cytosolic and microsomal fractions of the different tissues were prepared as previously described (4, 37). Human ARSA, ARSB, and ARSC cDNA clones were provided by Prof. K. von Figura (University of Göttingen, Göttingen, Germany) and expressed in V79 Chinese hamster lung fibroblast cells as previously described (25).

T₄, rT₃, 3,3'-T₂, and 3-iodothyronine were obtained from Henning Berlin GmbH & Co. (Berlin, Germany); T₃, E1S, 6-*n*-propyl-2-thiouracil (PTU) and bis-Tris propane (BTP) were purchased from Sigma (St. Louis, MO); [3',5'-¹²⁵I]T₄, [3'-¹²⁵I]T₃, and [³H]E1S were obtained from Amersham Pharmacia Biotech (Little Chalfont, UK); [3',5'-¹²⁵I]rT₃ and [3,3'-¹²⁵I]T₂ were prepared by radioiodination of 3,3'-T₂ and 3-iodothyronine, respectively (5). ¹²⁵I-labeled and unlabeled T₄S, rT₃S, T₃S, and 3,3'-T₂S were prepared by reaction of labeled and unlabeled T₄, rT₃, T₃, and 3,3'-T₂ with chlorosulfonic acid in dimethylformamide. They were purified by LH-20 chromatography (38).

Sulfatase assay

Iodothyronine sulfatase activity was assayed by incubation of 0.1 μ M unlabeled and 100,000 cpm ¹²⁵I-labeled T₄S, rT₃S, T₃S, or 3,3'-T₂S and 0.1 or 1 mM PTU (to block D1 activity) for 60 min at 37 C with the indicated amounts of tissue cytosol or microsomes or V79 cell homogenate in 0.2 ml buffer. Optimal assay conditions for the different sulfatases were determined by testing different buffers (0.1 M sodium acetate, sodium citrate, Tris-HCl, sodium phosphate, or BTP-HCl), pH values, and temperatures. The reactions were started by the addition of enzyme in ice-cold buffer and were stopped by the addition of 0.8 ml 0.1 M HCl. The mixtures were analyzed for T₄, rT₃, T₃, or 3,3'-T₂ formation by chromatography on Sephadex LH-20 minicolumns as previously described (39). Desulfation in complete reaction mixtures was corrected for background radioactivity detected in the corresponding Sephadex LH-20 fractions of control incubations without enzyme.

Estrogen sulfatase activity was analyzed by incubation of 0.1 μ M [³H]E1S for 0 (blank) or 30 min at 37 C with the indicated amounts of

tissue microsomes or V79 cell homogenate in 0.1 ml 0.1 M Tris-HCl (pH 7.2). The reactions were stopped by the addition of 0.4 ml 0.1 M Tris-HCl (pH 8.8), and the mixtures were extracted with 2.5 ml chloroform. Sulfate hydrolysis was quantified by counting 0.25 ml of the aqueous phase. The amount of E1S still present in complete reaction mixtures after 30 min at 37 C was compared with the amount of E1S present in the corresponding nonincubated reaction mixtures.

Results

Figure 1 shows the pH profiles of the desulfation of 0.1 μ M 3,3'-T₂S by rat liver and human liver microsomes and recombinant human ARSC obtained using acetate and BTP-HCl buffers. Rat liver microsomal sulfatase showed an optimum at pH 6.0–6.5 (Fig. 1A), human liver microsomal sulfatase at pH 6.0–7.5 (Fig. 1B), and ARSC at approximately pH 7.0 (Fig. 1C). At neutral pH, the different enzymes showed similar sulfatase activities in BTP-HCl and Tris-HCl buffers, but much lower activities in phosphate buffer (Fig. 2A). At acidic pH values, incubations of the different enzymes, in particular human liver, in citrate buffer strongly inhibited their 3,3'-T₂S sulfatase activities compared with incubations in acetate buffer (Fig. 2B). Similar results were obtained in buffers with or without 2 mM EDTA (not shown).

Figure 3 demonstrates the effects of temperature on the desulfation of 0.1 μ M 3,3'-T₂S by human and rat liver microsomes. The optimal temperature for human liver microsomes is 50 C, and that for rat liver microsomes is 70 C or higher.

Figure 4 presents the desulfation of 0.1 μ M T₄S, T₃S, rT₃S, and 3,3'-T₂S by recombinant human ARSC and human and rat placenta and liver microsomes at pH 7.2. ARSC showed similar activities toward 3,3'-T₂S and T₃S, whereas both rT₃S and T₄S were poor substrates for this enzyme. The substrate specificity of human placenta microsomes was similar to that of ARSC. Very high desulfation rates were observed in human liver microsomes, with a strong substrate preference for 3,3'-T₂S, which was hydrolyzed about 4 times faster than T₃S (*i.e.* desulfation rates of ~7.2 and 1.8 pmol/min·mg) and more than 10 times faster than the relatively poor substrates rT₃S and T₄S. Rat liver microsomes also showed a substrate preference for 3,3'-T₂S, which was desulfated twice as fast as T₃S; in rat placenta microsomes low desulfation rates (*i.e.* <0.1 pmol/min·mg) were observed with all iodothyronine sulfates. We also tested steroid sulfatase activities of ARSC and of human placenta and liver microsomes. Table 1 compares E1S and T₂S sulfatase activities of ARSC and the different human tissue microsomes. The low ratio of E1S to T₂S hydrolysis in liver microsomes differs largely from the high preference for E1S *vs.* T₂S hydrolysis by ARSC and human placenta microsomes. Tested at the optimum pH 5.5, soluble ARSA and ARSB as well as rat and human liver cytosols showed very low activity toward all iodothyronine sulfates (results not shown).

Figure 5 shows the desulfation of 3,3'-T₂S by ARSC, human liver, and human placenta microsomes as a function of the substrate concentration. As no saturation was reached even at the highest concentration of 50 μ M, K_m and maximum velocity values could not be calculated. Similar results were obtained when T₃S was used as substrate. Apparently all of these sulfatases have low affinity for iodothyronine sulfates, with K_m values greater than 50 μ M.




FIG. 1. Effects of pH on 3,3'-T₂S desulfation by rat liver or human liver microsomes, or ARSC. Reaction conditions were 0.1 μ M ¹²⁵I-labeled 3,3'-T₂S, 0.25 (A and C) or 0.05 (B) mg protein/ml, 0.1 mM PTU, and 60-min incubation in 0.1 M sodium acetate or BTP-HCl. Results are the means of triplicate determinations from a representative experiment.

Discussion

Normally, serum T₄S and T₃S levels are low (12, 40, 41). This is explained by the very rapid deiodination of these conjugates, as sulfation strongly induces the D1-catalyzed IRD of both T₄ and T₃ (7). However, under certain (patho)-physiological conditions, *e.g.* during fetal development and




FIG. 2. Effects of buffer on 3,3'-T₂S desulfation by rat liver, and human liver microsomes, and ARSC at pH 7.2 (A) or 5.5 (B). Reaction conditions were 0.1 μ M ¹²⁵I-labeled 3,3'-T₂S, 0.25 (rat liver and ARSC) or 0.05 (human liver) mg protein/ml, 0.1 mM PTU, and 60-min incubation in 0.1 M sodium phosphate (pH 7.2), 0.1 M Tris-HCl (pH 7.2), 0.1 M sodium acetate (pH 5.5), or 0.1 M sodium citrate (pH 5.5). Results are the means of triplicate determinations from a representative experiment.

nonthyroidal illness, possibly due to diminished D1 activity, plasma concentrations of iodothyronine sulfates are increased (12, 13, 16, 41). T₃S is considered to be biologically inert, as it has lost its affinity for the T₃ receptors (42). It could, however, serve as a reservoir from which active thyroid hormone is regenerated by tissue sulfatases or bacterial sulfatases in the intestine (8–11).

Recently, much research has been performed to develop inhibitors of steroid sulfatase (ARSC) because of their potential for the treatment of estrogen-dependent breast cancers (43–54). These studies have revealed some important structure-activity relations for compounds binding to the active site of ARSC. Furthermore, the crystal structures of arylsulfatases A and B have recently been elucidated (55, 56). Although the overall amino acid sequence homology is only about 20–30% between different arylsulfatases, the protein structures of all sulfatases share some important features. The active site of eukaryotic sulfatases contains a metal ion, probably Mg²⁺ (56, 57), and a formylglycine, generated by posttranslational modification of a cysteine residue (58–61). Residues interacting with Mg²⁺ and formylglycine are conserved among the members of the sulfatase family. Uhlhorn-Dierks *et al.* (57) proposed a catalytic mechanism for the hydrolysis of sulfates by sulfatases based on their structure and mutational analyses. An intermediate enzyme-sulfate complex is formed by the covalent binding of sulfate to the hydrated formylglycine (*i.e.* dihydroxyalanine). When the active site formylglycine is replaced by a serine (*i.e.* hydroxy-




FIG. 3. Effects of temperature on desulfation of 3,3'-T₂S by human or rat liver microsomes. Reaction conditions were 0.1 μ M [3,3'-¹²⁵I]T₂S, 0.25 (rat liver) or 0.025 (human liver) mg protein/ml, 1 mM PTU, and 60-min incubation in 0.1 M Tris-HCl (pH 7.2) at 20–70 C. Results are the means of two closely agreeing experiments.




FIG. 4. Desulfation of iodothyronine sulfates by ARSC, human or rat liver microsomes, or human or rat placenta microsomes. Reaction conditions were 0.1 μ M ¹²⁵I-labeled T₄S, T₃S, rT₃S, or 3,3'-T₂S; 0.25 (ARSC and rat liver), 0.05 (human liver), or 0.5 (human and rat placenta) mg protein/ml; 0.1 mM PTU; and 60-min incubation in 0.1 M Tris-HCl (pH 7.2). Results are the means of triplicate determinations from a representative experiment.

alanine), the intermediate enzyme-sulfate complex is trapped (62), which indicates that the second hydroxyl group of hydrated formylglycine is needed for sulfate release (57, 62).

Crystallographic analyses (55, 56, 63) also revealed structural homology between alkaline phosphatases and arylsulfatases. A functional relationship between the enzymes was shown by O'Brien *et al.* (64), who demonstrated that alkaline phosphatase exhibits a low level of sulfatase activity. They also showed inhibition of the phosphatase as well as the sulfatase activities of alkaline phosphatase by inorganic phosphate (64). Anderson *et al.* reported on steroidal and nonsteroidal phosphates that inhibited steroid sulfatase ac-

TABLE 1. Hydrolysis of E1S and 3,3'-T₂S by human ARSC, liver and placenta

Enzyme source	Hydrolysis		
	E1S	3,3'-T ₂ S	E1S/3,3'-T ₂ S
	(pmol/min-mg)		
ARSC-V79 homogenate	100	1.3	81
Human liver microsomes	1.6	7.2	0.21
Human placenta microsomes	52	0.34	150

Reaction conditions were: 0.1 μ M 3,[3'-¹²⁵I]T₂S, 0.1 mM PTU and 0.25 (ARSC), 0.05 (liver) or 0.5 (placenta) mg protein/ml, or 0.1 μ M [³H]E1S and 0.005 (ARSC), 0.5 (liver) or 0.01 (placenta) mg protein/ml, and 60-min incubation in 0.1 M Tris-HCl (pH 7.2). Results are the means of triplicate determinations from a representative experiment.


tivity (43). We demonstrated inhibition of the iodothyronine sulfatase activities by inorganic phosphate and citrate. Perhaps these anions block the active site of iodothyronine sulfatases. An alternative explanation is that citrate and phosphate inhibit iodothyronine sulfatase activity by complexing the enzyme-bound Mg²⁺. However, we did not observe inhibition of iodothyronine sulfatase activity in the presence of EDTA. Our results strongly suggest that iodothyronine sulfatase activities determined in phosphate buffers, as reported by others (9, 23), represent a marked underestimation of true enzyme levels.

Whereas significant sulfatase activity toward 3,3'-T₂S and T₃S was found in human placenta, in rat placenta activity toward these iodothyronine sulfates was much lower. This difference in activity may be due to the species difference. It should be noted, however, that whereas the rat placental tissue used in this study consisted of both the fetal as well as the maternal side of the placenta, the human placental tissue mainly consisted of the fetal side of the placenta, as most of the maternal side (decidua) is not expelled at spontaneous delivery. Furthermore, the rat placenta was isolated at embryonic d 20, *i.e.* 1 d before birth, whereas human placenta was obtained at full-term delivery. Therefore, besides the species difference, these differences in tissue composition and developmental stage may also contribute to the different sulfatase activities found in human and rat placenta.

We showed a pH optimum for rat liver microsomes at pH 6.0–6.5, for human liver microsomes at pH 6.0–7.5, and for arylsulfatase C at pH 7.0. The broader peak for the human and rat liver microsomes might indicate that different sulfatases, with different pH optima, are involved in the desulfation of 3,3'-T₂. Kung *et al.* (9) observed T₃S sulfatase activities in human and rat liver microsomes. E1S and DHEAS, both substrates for ARSC, inhibited T₃S hydrolysis with IC₅₀ values of approximately 10 μ M. The fact that high levels of E1S only partially inhibited T₃S desulfation, whereas high DHEAS concentrations produced complete inhibition, supports the involvement of multiple sulfatases, possibly including ARSC (9). However, these analyses were performed in phosphate buffer (9), which may strongly affect the contributions of different sulfatases.

The optimal temperature of iodothyronine sulfatase activities is 50 C in human liver microsomes and at least 70 C in rat liver microsomes. The high thermostability of these sulfatases is in agreement with the temperature optimum of 60 C for ARSC (65). ARSC and the sulfatase activities in

FIG. 5. Effects of substrate concentration on the desulfation of 3,3'-T₂S by ARSC, human placenta, or human liver microsomes. Reaction conditions were 1–50 μM [3,3'-¹²⁵I]T₂S; 0.05 (liver), 0.25 (ARSC), or 0.5 (placenta) mg protein/ml; 1 mM PTU; and 60-min incubation in 0.1 M Tris-HCl (pH 7.2). Results are the means of triplicate determinations from a representative experiment.



human liver and placenta microsomes have high K_m values for iodothyronine sulfates. The different substrate specificities of the iodothyronine sulfatase activity in human liver *vs.* ARSC and placenta as well as the finding that the ratio of E1S to T₂S hydrolysis in human liver differs greatly from that in ARSC and placenta suggest that in human liver additional sulfatases to ARSC contribute to the hydrolysis of iodothyronine sulfates, in particular T₂S. However, ARSD, ARSE, and ARSF are not likely candidates, as 1) both ARSE and ARSF are thermolabile, whereas iodothyronine sulfatase activity appears thermostable (33, 34); and 2) ARSD does not possess arylsulfatase activity (34, 35).

It is remarkable that although 3,3'-T₂ is the preferred substrate for sulfotransferases, 3,3'-T₂S is the preferred substrate for (human liver) sulfatase. Thus, reversible sulfation/desulfation seems a more important metabolic pathway for 3,3'-T₂ than for T₄, T₃, and rT₃. This may reflect restrictions in the active sites of the sulfotransferase and sulfatase to accommodate bulky substrates with more than two iodine substituents. However, a physiological role for 3,3'-T₂ is not excluded. Although its affinity for the nuclear thyroid hormone receptors is low (17), 3,3'-T₂ has been shown to stimulate mitochondrial respiration in different tissues (66).

In conclusion, we have identified arylsulfatase C as a high K_m iodothyronine sulfatase that is most likely the main enzyme responsible for the hydrolysis of iodothyronine sulfates in human placenta and to some extent in human liver. Further investigations are needed to determine the possible importance of other, still unidentified, microsomal sulfatases in hydrolysis of iodothyronine sulfates in the liver and perhaps other tissues. This information may contribute to the understanding of the role of sulfation-desulfation in the regulation of thyroid hormone bioactivity, in particular during fetal development.

Acknowledgments

We thank Prof. K. von Figura for his generous gifts of ARSA, ARSB, and ARSC cDNA clones, and Sheila Sharp for expressing of ARS cDNAs in V79 cells.

Received August 7, 2001. Accepted November 9, 2001.

Address all correspondence and requests for reprints to: Dr. Theo J. Visser, Department of Internal Medicine, Room Bd 234, Erasmus University Medical School, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands. E-mail: visser@inw3.azr.nl.

This work was supported by the Sophia Foundation for Medical Research (Project 211), the Commission of the European Communities (Contract BMH1-CT92-0097 and QL3-2000-00930), and the Tenovus Scotland/Leng Trust.

References

- Rikke BA, Roy AK 1996 Structural relationships among members of the mammalian sulfotransferase gene family. *Biochim Biophys Acta* 1307:331–338
- Weinshilboum RM, Otterness DM, Aksoy IA, Wood TC, Her C, Raftogianis RB 1997 Sulfotransferase molecular biology: cDNAs and genes. *FASEB J* 11:3–14
- Falany CN 1997 Enzymology of human cytosolic sulfotransferases. *FASEB J* 11:206–216
- Visser TJ, Kaptein E, Terpstra OT, Krenning EP 1988 Deiodination of thyroid hormone by human liver. *J Clin Endocrinol Metab* 67:17–24
- Toyoda N, Kaptein E, Berry MJ, Harney JW, Larsen PR, Visser TJ 1997 Structure-activity relationships for thyroid hormone deiodination by mammalian type I iodothyronine deiodinases. *Endocrinology* 138:213–219
- Visser TJ, van Buuren JCJ, Rutgers M, Eelkman Rooda SJ, de Herder WW 1990 The role of sulfation in thyroid hormone metabolism. *Trends Endocrinol Metab* 1:211–218
- Visser TJ 1994 Role of sulfation in thyroid hormone metabolism. *Chem Biol Interact* 92:293–303
- Santini F, Hurd RE, Chopra IJ 1992 Metabolism of 3,5,3'-triiodothyronine sulfate by tissues of the fetal rat: a consideration of the role of desulfation of 3,5,3'-triiodothyronine sulfate as a source of T₃. *Pediatr Res* 31:541–544
- Kung MP, Spaulding SW, Roth JA 1988 Desulfation of 3,5,3'-triiodothyronine sulfate by microsomes from human and rat tissues. *Endocrinology* 122:1195–1200
- Santini F, Hurd RE, Lee B, Chopra IJ 1993 Thyromimetic effects of 3,5,3'-triiodothyronine sulfate in hypothyroid rats. *Endocrinology* 133:105–110
- Hazenbergh MP, de Herder WW, Visser TJ 1988 Hydrolysis of iodothyronine conjugates by intestinal bacteria. *FEMS Microbiol Rev* 54:9–16
- Chopra IJ, Wu SY, Chua Teco GN, Santini F 1992 A radioimmunoassay for measurement of 3,5,3'-triiodothyronine sulfate: studies in thyroidal and non-thyroidal diseases, pregnancy, and neonatal life. *J Clin Endocrinol Metab* 75:189–194
- Santini F, Cortelazzi D, Baggiani AM, Marconi AM, Beck-Peccoz P, Chopra IJ 1993 A study of the serum 3,5,3'-triiodothyronine sulfate concentration in normal and hypothyroid fetuses at various gestational stages. *J Clin Endocrinol Metab* 76:1583–1587
- Wu SY, Polk D, Wong S, Reviczky A, Vu R, Fisher DA 1992 Thyroxine sulfate is a major thyroid hormone metabolite and a potential intermediate in the monodeiodination pathways in fetal sheep. *Endocrinology* 131:1751–1756
- Wu SY, Polk DH, Huang SW, Reviczky A, Wang K, Fisher DA 1993 Sulfate

- conjugates of iodothyronines in developing sheep: effect of fetal hypothyroidism. *Am J Physiol* 265:E115–E120
16. Polk DH 1995 Thyroid hormone metabolism during development. *Reprod Fertil Dev* 7:469–477
 17. Oppenheimer JH, Schwartz HL 1997 Molecular basis of thyroid hormone-dependent brain development. *Endocr Rev* 18:462–475
 18. Porterfield SP, Hendrich CE 1993 The role of thyroid hormones in prenatal and neonatal neurological development: current perspectives. *Endocr Rev* 14:94–106
 19. Pop VJ, Kuijpers JL, van Baar AL, Verkerk G, van Son MM, de Vijlder JJ, Vulsma T, Wiersinga WM, Drexhage HA, Vader HL 1999 Low maternal free tyrosine concentrations during early pregnancy are associated with impaired psychomotor development in infancy. *Clin Endocrinol (Oxf)* 50:149–155
 20. Obregón MJ, Calvo RM, Escobar del Rey F, Morreale de Escobar G 1998 Thyroid hormones and fetal development. In: Pinchera A, Mann K, Hostalek U, eds. *The thyroid and age*. Stuttgart: Schattauer; 49–73
 21. Santini F, Chopra IJ, Wu SY, Solomon DH, Chua Teco GN 1992 Metabolism of 3,5,3'-triiodothyronine sulfate by tissues of the fetal rat: a consideration of the role of desulfation of 3,5,3'-triiodothyronine sulfate as a source of T₃. *Pediatr Res* 31:541–544
 22. Richard K, Hume R, Kaptein E, Visser TJ, Coughtrie MWH 2001 Sulfation of thyroid hormone and dopamine during human development: ontogeny of phenol sulfotransferases and arylsulfatase in liver, lung and brain. *J Clin Endocrinol Metab* 86:2734–2742
 23. Huang WS, Kuo SW, Chen WL, Hsieh KS, Wu SY 1996 Maturation of hepatic desulfation activity in developing rats. *J Formos Med Assoc* 95:435–439
 24. Parenti G, Meroni G, Ballabio A 1997 The sulfatase gene family. *Curr Opin Genet Dev* 7:386–391
 25. Coughtrie MWH, Sharp S, Maxwell K, Innes NP 1998 Biology and function of the reversible sulfation pathway catalysed by human sulfotransferases and sulfatases. *Chem Biol Interact* 109:3–27
 26. Selmi S, Maire I, Rousset B 1989 Evidence for the presence of a very high concentration of arylsulfatase A in the pig thyroid: identification of arylsulfatase A subunits as the two major glycoproteins in purified thyroid lysosomes. *Arch Biochem Biophys* 273:170–179
 27. Kester MHA, van Dijk CH, Tibboel D, Meinel W, Glatt H, Falany CN, Coughtrie MWH, Bergman A, Safe SH, Kuiper GGJM, Schuur AG, Brouwer A, Visser TJ 1999 Sulfation of thyroid hormone by estrogen sulfotransferase. *J Clin Endocrinol Metab* 84:2577–2580
 28. Burns GRJ 1983 Purification and partial characterization of arylsulfatase C from human placental microsomes. *Biochim Biophys Acta* 759:199–204
 29. Kawano JI, Kotani T, Ohtaki S, Minamino N, Matsuo H, Oinuma T, Aikawa E 1989 Characterization of rat and human steroid sulfatases. *Biochim Biophys Acta* 997:199–205
 30. Moriyasu M, Ito A, Omura T 1982 Purification and properties of arylsulfatase C from rat liver microsomes. *J Biochem* 92:1189–1195
 31. Park IH, Han PK, Jo DH 1997 Distribution and characterization of neurosteroid sulfatase from the bovine brain. *J Steroid Biochem Mol Biol* 62:315–320
 32. Kuss E 1994 The fetoplacental unit of primates. *Exp Clin Endocrinol* 102:135–165
 33. Franco B, Meroni G, Parenti G, Levilliers J, Bernard L, Gebbia M, Cox L, Maroteaux P, Sheffield L, Rappold GA, Andria G, Petit C, Ballabio A 1995 A cluster of sulfatase genes on Xp22.3: mutations in chondrodysplasia punctata (CDPX) and implications for warfarin embryopathy. *Cell* 81:15–25
 34. Puca A, Zollo M, Repetto M, Andolfi G, Guffianti A, Simon G, Ballabio A, Franco B 1997 Identification by shotgun sequencing, genomic organization, and functional analysis of a fourth arylsulfatase gene (ARSF) from the Xp22.3 region. *Genomics* 42:192–199
 35. Urbitsch P, Salzer MJ, Hirschmann P, Vogt PH 2000 Arylsulfatase D gene in Xp22.3 encodes two protein isoforms. *DNA Cell Biol* 19:765–773
 36. Daniele A, Parenti G, d'Addio M, Andria G, Ballabio A, Meroni G 1998 Biochemical characterization of arylsulfatase E and functional analysis of mutations found in patients with X-linked chondrodysplasia punctata. *Am J Hum Genet* 62:562–572
 37. Visser TJ, Kaptein E, Gijzel A, de Herder WW, Cannon ML, Bonthuis F, de Greef WJ 1996 Effects of thyroid status and thyrostatic drugs on hepatic glucuronidation of iodothyronines and other substrates in rats. Induction of phenol UDP-glucuronyltransferase by methimazole. *Endocrine* 4:79–85
 38. Mol JA, Visser TJ 1985 Synthesis and some properties of sulfate esters and sulfamates of iodothyronines. *Endocrinology* 117:1–7
 39. Otten MH, Mol JA, Visser TJ 1983 Sulfation preceding deiodination of iodothyronines in rat hepatocytes. *Science* 221:81–83
 40. Eelkman Rooda SJ, Kaptein E, Visser TJ 1989 Serum triiodothyronine sulfate in man measured by radioimmunoassay. *J Clin Endocrinol Metab* 69:552–556
 41. Chopra IJ, Wu SY, Chua Teco GN, Santini F 1993 A radioimmunoassay for measurement of thyroxine sulfate. *J Clin Endocrinol Metab* 76:145–150
 42. Spaulding SW, Smith TJ, Hinkle PM, Davis FB, Kung MP, Roth JA 1992 Studies on the biological activity of triiodothyronine sulfate. *J Clin Endocrinol Metab* 74:1062–1067
 43. Anderson C, Freeman J, Lucas LH, Farley M, Dalhoumi H, Widlanski TS 1997 Estrone sulfatase: probing structural requirements for substrate and inhibitor recognition. *Biochemistry* 36:2586–2594
 44. Selcer KW, Jagannathan S, Rhodes ME, Li PK 1996 Inhibition of placental estrone sulfatase activity and MCF-7 breast cancer cell proliferation by estrone-3-amino derivatives. *J Steroid Biochem Mol Biol* 59:83–91
 45. Kyle KW, Hegde PV, Li PK 1997 Inhibition of estrone sulfatase and proliferation of human breast cancer cells by nonsteroidal (*p*-O-sulfamoyl)-N-alkanoyl tyramines. *Cancer Res* 57:702–707
 46. Chu GH, Milano S, Kluth L, Rhodes M, Boni R, Johnson DA, Li PK 1997 Structure-activity relationship studies of the amide functionality in *p*-O-sulfamoyl-N-alkanoyl tyramines as estrone sulfatase inhibitors. *Steroids* 62:530–535
 47. Li PK, Chu GH, Guo JP, Peters A, Selcer KW 1998 Development of potent non-estrogenic estrone sulfatase inhibitors. *Steroids* 63:425–432
 48. Huang Z, Fasco MJ, Kaminsky LS 1997 Inhibition of estrone sulfatase in human liver microsomes by quercetin and other flavonoids. *J Steroid Biochem* 63:1–3
 49. Purohit A, Hejaz HA, Woo LW, van Strien AE, Potter BV, Reed MJ 1999 Recent advances in the development of steroid sulphatase inhibitors. *J Steroid Biochem Mol Biol* 69:227–238
 50. Pasqualini JR, Chetrite GS 1999 Estrone sulfatase versus estrone sulfotransferase in human breast cancer: potential and clinical applications. *J Steroid Mol Biol* 69:287–292
 51. Purohit A, Woo LW, Potter BV, Reed MJ 2000 In vivo inhibition of estrone sulfatase activity and growth of nitrosomethylurea-induced mammary tumors by 667 COUMATE. *Cancer Res* 60:3394–3396
 52. Zhu BT, Kosh JW, Fu J, Cai MX, Conney AH 2000 Strong inhibition of estrone-3-sulfatase activity by pregnenolone 16 α -carbonitrile but not by several analogs lacking a 16 α -nitrile group. *Steroids* 65:521–527
 53. Boivin RP, Luu-The V, Lachance R, Labrie F, Poirier D 2000 Structure-activity relationships of 17 α -derivatives of estradiol as inhibitors of steroid sulfatase. *J Med Chem* 16:4465–4478
 54. Billich A, Nussbaumer P, Lehr P 2000 Stimulation of MCF-7 breast cancer cell proliferation by estrone sulfate and dehydroepiandrosterone sulfate: inhibition by novel non-steroidal sulfatase inhibitors. *J Steroid Mol Biol* 73:225–235
 55. Bond CS, Clements PR, Ashby SJ, Collyer CA, Harrop SJ, Hopwood JJ, Guss JM 1996 Structure of human lysosomal sulfatase. *Structure* 15:277–289
 56. Lukatela G, Krauss N, Theis K, Selmer T, Giesemann V, von Figura K, Saenger W 1998 Crystal structure of human arylsulfatase A: the aldehyde function and the metal ion at the active site suggest a novel mechanism for sulfate ester hydrolysis. *Biochemistry* 37:3654–3664
 57. Uhlhorn-Dierks G, Kolter T, Sandhoff K 1998 How does nature cleave sulfuric acid esters? A novel posttranslational modification of sulfatases. *Angew Chem Int Ed* 37:2453–2455
 58. Dierks T, Miech C, Hummerjohann J, Schmidt B, Kertesz MA, von Figura K 1998 Posttranslational formation of formylglycine in prokaryotic sulfatases by modification of either cysteine or serine. *J Biol Chem* 273:25560–25564
 59. Dierks T, Schmidt B, von Figura K 1997 Conversion of cysteine to formylglycine: a protein modification in the endoplasmic reticulum. *Proc Natl Acad Sci USA* 94:11963–11968
 60. Schmidt B, Selmer T, Ingendoh A, von Figura K 1995 A novel amino acid modification in sulfatases that is defective in multiple sulfatase deficiency. *Cell* 82:271–278
 61. Dierks T, Lecca MR, Schlotterhose P, Schmidt B, von Figura K 1999 Sequence determinants directing conversion of cysteine to formylglycine in eukaryotic sulfatases. *EMBO J* 18:2084–2091
 62. Recksiek M, Selmer T, Dierks T, Schmidt B, von Figura K 1998 Sulfatases, trapping of the sulfated enzyme intermediate by substituting the active site formylglycine. *J Biol Chem* 273:6096–6103
 63. Sowadski JM, Handschumacher MD, Krishna Murthy HM, Foster BA, Wykoff HW 1985 Refined structure of alkaline phosphatase from *Escherichia coli* at 2.8 Å resolution. *J Mol Biol* 186:417–433
 64. O'Brien PJ, Herschlag D 1998 Sulfatase activity of *E. coli* alkaline phosphatase demonstrates a functional link to arylsulfatases, an evolutionary related enzyme family. *J Am Soc* 120:12369–12370
 65. Chibbar R, Mitchell BF 1990 Steroid sulfohydrolase in human chorion and decidua: studies using pregnenolone sulfate and dehydroepiandrosterone sulfate as substrate. *J Clin Endocrinol Metab* 70:1693–1701
 66. Moreno M, Lanni A, Lombardi A, Gaglia F 1997 How the thyroid controls metabolism in the rat: different roles for triiodothyronine and diiodothyronines. *J Physiol* 505:529–538